395; 95% CI, 0.180-0.896; P = 0.021). Age of onset below 18 was a significant risk factor (HR, 1.963; 95% CI, 1.21-3.20; P = 0.007) for the use of immunosuppressants in CD. Extent of disease was a significant factor associated with surgical resection (p = 0.012) in univariate analysis but not in multivariate analysis. Extensive disease in UC was a significant risk factor in multivariate

cox model (HR, 3.558; 95% CI, 1.32-9.58; P = 0.012) for primary use of immunosuppressants. Conclusion: In CD, colonic disease were associated with decreased risk while stricturing and penetrating behavior were associated with increased risk of surgical resection. In UC, extensive disease was associated with the need for immunosuppressants. Key Word(s): 1. inflammatory bowel disease; 2. bowel resection Presenting Author: GOVIND K MAKHARIA Additional Authors: GOVIND K MAKHARIA, Selleckchem YAP-TEAD Inhibitor 1 ABHISHEK AGNIHOTRI,

GSK1120212 mw SUDIPTO CHAUDHARY, UC GHOSHAL, MANISH K PATHAK, ASHA MISHRA, SIDDHARTHA DATTA GUPTA, RAJU SHARMA, RM PANDEY, VINEET AHUJA, SK SHARMA, BS RAMAKRISHNA Corresponding Author: GOVIND K MAKHARIA Affiliations: All India Institute of Medical Sciences, All India Institute of Medical Sciences, Christian Medical College, Sanjay Gandhi Postgraduate Institute of Medical Sc, All India Institute of Medical Sciences, All India Institute of Medical Sciences, All India Institute of Medical Sciences, All India Institute of Medical Sciences, All India Institute of Medical Sciences,All India Institute of Medical Thymidine kinase Sciences, All India Institute of Medical Sciences, SRM Institute of Medical Sciences Objective: Whether patients with abdominal tuberculosis

(both gastrointestinal and peritoneal) should be treated with six months or nine months is a debatable. There is also a lack of data on the efficacy of short course intermittent therapy in treatment of abdominal tuberculosis. We conducted a multicenter single blinded randomized controlled trial to assess the efficacy of 6 months and 9 months of anti-tuberculous therapy (ATT) in abdominal tuberculosis using Directly Observed Therapy Short Course (DOTS). Methods: Of 499 patients screened, 197 patients with abdominal tuberculosis (gastrointestinal-154, peritoneal-40, mixed-3) were randomized to receive 6-mo (Group A, n = 104) and 9-mo (Group B, n = 93) of ATT using DOTS strategy. All patients were evaluated for primary end point (complete clinical response, partial clinical response, no response, or death) and secondary end point (mucosal healing). Patients were followed up further for one year after completion of treatment to assess recurrence. Results: Both groups had similar baseline characteristics, clinical manifestations, site of disease, proportion of definitive or presumptive diagnosis of tuberculosis. Per protocol analysis showed no difference in complete clinical response (91.5% vs 90.8%, P = 0.882) between group A and group B.